Mesoblast Inc. | TalkMarkets

Latest Posts

The Dream Team Disruptors - Einstein's In Biopharma 2020-2021

Article By: James Gornick

Tuesday, November 24, 2020 7:18 AM EDT

The trends in the final months of 2020 and moving into 2021 have assembled "The Dream-Team" in saving many lives and the losses in functionalities in those infected with COVID-19 World-Wide Pandemic.

In this article: AZN, JNJ, PFE, CYDY, ABIO, REGN, SPPI, MRNA, AXDX, CAPR, MESO, NVS Also: INO, SRNE, NVAX, DVAX, CRSP

Read

Week In Review: Acletis Raising $457 Million In Hong Kong IPO At $2 Billion Valuation

Article By: ChinaBio® Today

Saturday, July 21, 2018 4:12 PM EDT

Ascletis BioScience, the Hangzhou biopharma with a novel treatment for hepatitis C, may raise as much as $457 million in its upcoming Hong Kong IPO, a debut offering that values the company at $2 billion.

In this article: MESO

Read

Mesoblast - Chart Of The Day

Article By: Jim Van Meerten

Wednesday, March 8, 2017 11:26 PM EDT

Since the Trend Spotter signaled a buy in 2/17 the stock gained 18.72%.

In this article: MESO

Read

Four Best Biotech Stocks Of The First Quarter Of 2016

Article By: Zacks Investment Research

Sunday, April 3, 2016 7:19 AM EDT

The entry of the first FDA-approved biosimilar, Zarxio, a biosimilar version of Amgen’s blockbuster drug, Neupogent, last year has left biotech companies vying to enter this high revenue generating space. Biosimilars are the next big thing.

In this article: KIN, CRMD, ALIOF, MESO Also: AMGN, GILD, SHPG, BXLT

Read